First substantial evidence in support of ‘chelation theraphy’ in ‘coronary disease’

· TGI - Health

The trial sponsored by two NIH institutes, the National Center for Complementary and Alternative Medicine and the National Heart Lung and Blood Institute, to assess chelaton therapy in coronary disease suggests that there is substantial evidence in support of chelation theraphy in coronary disease.

TACT was funded by the NIH more than a decade ago as part of a much-publicized initiative to study the claims of alternative medicine. Now the results of TACT will likely provide ammunition to chelation defenders.

TACT was a double blind study testing active or placebo infusions of chelation in stable patients with a history of MI. The study was conducted on about  1,708 patients.

Study Highlights (AHA press release ):

  • Patients with prior heart attacks enrolled in a clinical trial of a weekly chelation infusion regiment that included disodium EDTA and vitamin C had fewer cardiovascular disease complications than those who received placebo infusions.
  • Chelation therapy removes heavy metals like lead and iron from the body. Disodium EDTA, the agent used in the study, does not have an FDA indication.
  • Investigators caution that the results need to be reproduced and understood before consideration of clinical application.

Unless the  effect will be reproducible and one can show  a consistent effect across studies it will be difficult for chelation to enter the mainstream of other cardiovascular therapies,” says Lamas.

{Gervasio A.  (Tony) Lamas, M.D., is a lead author of the study and chief of Columbia University Division of Cardiology at Mount Sinai Medical Center in Miami Beach, Fla}

Metal-EDTA chelate

Metal-EDTA chelate (Photo credit: Wikipedia)

He says “although not approved by the Food and Drug Administration for treating heart disease, chelation therapy has been used for over 50 years and has generally been believed by conventional medical practitioners and cardiologists to be without value. A definitive answer on chelation therapy will take much additional research. The most exciting part of this study is that there may be an unexpected signal of benefit. We need to understand whether the signal is true, or whether it occurred by chance.”

Study details :
The patients in the trial were
– 82 percent male,
– 94 percent Caucasian and about half were obese.
– All had experienced a previous heart attack,
– 83 percent already had bypass surgery, stent implantation or balloon angioplasty
– 32 percent had diabetes,
– 68 percent had high blood pressure and
– 73 percent had been prescribed cholesterol-lowering statins.
– Patients were followed for an average of 55 months
– The trial was conducted in 134 sites in the United States and Canada from 2002-2011
– Each patient received 40 infusions, each lasting at least three hours.
– The first 30 infusions were one week apart. The last 10 were two weeks to two months apart depending on the patient’s schedule.
– All told, researchers delivered 55,222 infusions.
Lamas said there is still much work to do before the treatment would be considered standard.
souce: forbes

1 Comment

Comments RSS

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: